North America Is Expected To Dominate The Global Bio-Engineered Stent Market And This Is Attributed To The High Presence Of The Geriatric Population
The growing prevalence of cardiovascular diseases such as ischemic heart disease and coronary heart disease is significantly fueling the growth of the bio-engineered stent market . According to the U.S. National Library of Medicine, IHD (ischemic heart disease) affects around 126 million individuals (1,655 per 100,000), which is approximately 1.72% of the world’s population. Nine million deaths were caused by IHD globally. According to the National Center for Chronic Disease Prevention and Health Promotion, about 655,000 Americans die from heart disease each year—that’s 1 in every 4 deaths. Bio-engineered stents are used to expand the blood vessel to prevent a blockage of arteries. In September 2020, OrbusNeich Medical Co. Ltd. has announced that the National Medical Products Administration (NMPA) has granted market approval for the COMBO BIO-ENGINEERED SIROLIMUS ELUTING STENT in China. In May 2017, Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and U...